PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 129 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2020. The put-call ratio across all filers is 2.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $58,660 | -63.4% | 17,994 | -40.4% | 0.00% | – |
Q1 2024 | $160,071 | +35.9% | 30,202 | +11.1% | 0.00% | – |
Q4 2023 | $117,750 | +75867.7% | 27,194 | +45991.5% | 0.00% | – |
Q3 2023 | $155 | -96.0% | 59 | -94.7% | 0.00% | – |
Q2 2023 | $3,894 | +29.8% | 1,103 | 0.0% | 0.00% | – |
Q1 2023 | $3,000 | +59900.0% | 1,103 | 0.0% | 0.00% | – |
Q4 2022 | $5 | -99.9% | 1,103 | -61.3% | 0.00% | – |
Q3 2022 | $7,000 | +16.7% | 2,849 | +27.6% | 0.00% | – |
Q2 2022 | $6,000 | -98.5% | 2,232 | -98.4% | 0.00% | – |
Q1 2022 | $412,000 | -5.7% | 142,881 | -0.4% | 0.00% | – |
Q4 2021 | $437,000 | -58.1% | 143,497 | -3.7% | 0.00% | – |
Q3 2021 | $1,044,000 | -27.9% | 148,940 | -5.6% | 0.00% | – |
Q2 2021 | $1,448,000 | -9.8% | 157,699 | -4.5% | 0.00% | – |
Q1 2021 | $1,605,000 | -22.6% | 165,138 | -18.3% | 0.00% | – |
Q4 2020 | $2,074,000 | -16.2% | 202,129 | -17.9% | 0.00% | – |
Q3 2020 | $2,476,000 | -12.8% | 246,336 | -9.5% | 0.00% | -100.0% |
Q2 2020 | $2,840,000 | +332.3% | 272,273 | +250.0% | 0.00% | – |
Q1 2020 | $657,000 | -14.6% | 77,794 | -11.5% | 0.00% | – |
Q4 2019 | $769,000 | -22.7% | 87,908 | -4.8% | 0.00% | – |
Q3 2019 | $995,000 | -14.9% | 92,310 | +0.3% | 0.00% | – |
Q2 2019 | $1,169,000 | -71.4% | 92,055 | -12.7% | 0.00% | -100.0% |
Q1 2019 | $4,090,000 | +94.6% | 105,453 | +2.1% | 0.00% | – |
Q4 2018 | $2,102,000 | -58.7% | 103,302 | -6.9% | 0.00% | -100.0% |
Q3 2018 | $5,086,000 | -14.9% | 110,926 | +9.8% | 0.00% | 0.0% |
Q2 2018 | $5,974,000 | +124.5% | 101,014 | +158.3% | 0.00% | 0.0% |
Q1 2018 | $2,661,000 | -75.3% | 39,107 | -64.1% | 0.00% | -50.0% |
Q4 2017 | $10,779,000 | +12886.7% | 109,039 | +15344.6% | 0.00% | – |
Q3 2017 | $83,000 | +72.9% | 706 | +28.8% | 0.00% | – |
Q2 2017 | $48,000 | -98.5% | 548 | -99.4% | 0.00% | -100.0% |
Q1 2017 | $3,174,000 | +15.4% | 85,338 | -4.7% | 0.00% | 0.0% |
Q4 2016 | $2,750,000 | -65.1% | 89,569 | -23.8% | 0.00% | -50.0% |
Q3 2016 | $7,882,000 | +14.1% | 117,547 | -49.3% | 0.00% | 0.0% |
Q2 2016 | $6,907,000 | +33.2% | 231,875 | +31.4% | 0.00% | +100.0% |
Q1 2016 | $5,185,000 | +6.5% | 176,530 | +184.3% | 0.00% | 0.0% |
Q4 2015 | $4,869,000 | -74.4% | 62,102 | -75.4% | 0.00% | -80.0% |
Q3 2015 | $19,019,000 | -44.9% | 252,382 | -14.6% | 0.01% | -37.5% |
Q2 2015 | $34,505,000 | -36.3% | 295,536 | +28.8% | 0.01% | -33.3% |
Q1 2015 | $54,172,000 | +50.5% | 229,436 | +20.7% | 0.01% | +50.0% |
Q4 2014 | $35,991,000 | -45.3% | 190,160 | -31.1% | 0.01% | -50.0% |
Q3 2014 | $65,835,000 | +113.5% | 275,959 | -40.9% | 0.02% | +100.0% |
Q2 2014 | $30,834,000 | -30.1% | 467,180 | +10.4% | 0.01% | -33.3% |
Q1 2014 | $44,085,000 | -9.8% | 423,335 | -10.3% | 0.01% | -14.3% |
Q4 2013 | $48,868,000 | +97.4% | 472,018 | +2.3% | 0.01% | +100.0% |
Q3 2013 | $24,756,000 | -23.8% | 461,354 | -37.0% | 0.01% | -30.0% |
Q2 2013 | $32,509,000 | – | 732,666 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 507,500 | $121,074,000 | 24.90% |
BB BIOTECH AG | 476,991 | $113,796,000 | 4.63% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $1,356,668,000 | 3.35% |
WEATHERBIE CAPITAL, LLC | 101,055 | $24,109,000 | 2.26% |
Avalon Global Asset Management LLC | 16,000 | $3,817,000 | 2.24% |
Redmile Group, LLC | 51,025 | $12,173,000 | 1.41% |
Fernwood Investment Management, LLC | 6,700 | $1,598,000 | 1.38% |
Iguana Healthcare Management, LLC | 10,000 | $2,386,000 | 1.27% |
LMR Partners LLP | 56,632 | $13,510,000 | 1.08% |
FRANKLIN STREET ADVISORS INC /NC | 21,990 | $5,246,000 | 1.00% |